Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05120271 |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) |
| active not recruiting |
| Phase 1 / Phase 2 |
| 7 |
| Sotio Biotech Inc.INDUSTRY |
| 2 |
| Dec 5, 2025 |
| clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT05178693 | Lutathera and ASTX727 in Neuroendocrine Tumours(LANTana) | recruiting | Phase 1 | 27 | Imperial College LondonOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | terminated | Phase 1 / Phase 2 | 31 | NeoImmuneTechINDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC | suspended | Phase 1 | 6 | AmgenINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06940440 | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | recruiting | Phase 1 | 9 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206563 | Penfluridol for Relapsed/Refractory Small Cell Cancers | not yet recruiting | Phase 1 / Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05077384 | Open-label Study of Surufatinib in Japanese Patients | completed | Phase 1 / Phase 2 | 36 | HutchmedINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 10 | STCube, Inc.INDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07132957 | A Study of AL8326 in Healthy Subjects | completed | Phase 1 | 6 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT07063407 | Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 50 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 0 | Jul 14, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06732505 | A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens | recruiting | Phase 1 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03466216 | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET | terminated | Phase 1 | 33 | Orano Med LLCINDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05870423 | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors(PRRT-PARPi) | recruiting | Phase 1 | 24 | Erasmus Medical CenterOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.(LUPER) | completed | Phase 1 / Phase 2 | 28 | Antonio Calles BlancoOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 11, 2025source: clinicaltrials